Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In
  • Become a Member
  • MB Vision
  • Members
    • Become a Member
      • Types & Rates
    • Benefits
      • Savings and Rewards
    • Member News
    • Member Events
    • Career Center
    • Directory
    • Pay Company Dues
    • FAQs
  • Events
    • Upcoming
    • Types of Events
    • Sponsorship Opportunities
    • The State of Possible Conference
    • Align Summit
    • Member Events
  • Innovation
    • About
    • Drive
      • Application
      • Alumni
      • Partners – MassBio
      • Partners – SCbio
      • Get Involved
      • FAQs
    • CEO & Founder Link
    • Align Summit
    • Partnering
    • Sponsorship Opportunities
  • Savings
    • MassBioEdge
  • Conference Center
    • About MassBioHub
    • Packages & Special Offers
    • Venue Specifications
    • Reserve Today
  • Policy & Advocacy
    • Policy & Advocacy Efforts
    • Diversity, Equity, and Inclusion
      • DEI Report
      • Resource Center
      • Open Letter 2.0
      • Bioversity
    • Economic Development
      • BioReady® Communities
    • Workforce Development
      • Bioversity
    • Vision 2030
    • This is the place.
    • Industry Reports
      • Federal Actions Impact Report
      • Industry Snapshot
      • Biopharma Funding Report
      • DEI Report
      • MA Life Sciences Workforce
  • About
    • About MassBio
    • News & Thought Leadership
    • MB Vision
    • The Studio at Kendall Square
    • Sponsorship Opportunities
    • Staff
    • Board
    • Contact Us
  • Sign In
  • Become a Member
  • MB Vision
Open search form

Member Directory

Click to Open Main Menu

Pinetree Therapeutics, Inc

Life Sciences | Drug Development
Cambridge, MA 6179452309 Website LinkedIn

Overview

Pinetree Therapeutics is an award-winning, pre-clinical stage biotechnology company based in Cambridge, Massachusetts. Dedicated to addressing unmet medical needs, such as drug resistance and tumor recurrence in targeted therapy, Pinetree Therapeutics is advancing the field with its novel AbReptorTM platform. While the primary focus is on oncology, Pinetree Therapeutics is expanding pipelines to other areas as well.

 

The AbReptorTM platform enables the development of multi-specific antibodies designed to outperform conventional inhibitors and ADCs (Antibody Drug Conjugate) by degradation. Unlike traditional inhibitors, which are limited in their mechanism of action (blocking the signaling pathway), our antibodies demonstrate superior efficacy in targeting and degrading disease proteins. The platform’s focus is on targeted degradation of membrane-bound and extracellular proteins, offering a distinct advantage over conventional inhibitors and intracellular degraders like PROTACs or GLUEs. Additionally, the unique mechanism of our platform has yielded promising preclinical results in ADC (/DAC/ARC) application, demonstrating its potential to significantly advance the field.

 

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • News & Thought Leadership
  • Pay Company Dues
  • Join Today
  • Contact
  • Privacy Policy
  • © 2025 All Rights Reserved